What is the recommended initial insulin dosing regimen for a 70‑kg adult with type 1 diabetes, including basal and rapid‑acting (prandial) doses and guidance on adjustments?

Insulin Dosage in Type 1 Diabetes

For a 70-kg adult with type 1 diabetes, start with a total daily dose of 0.5 units/kg (35 units/day), split approximately 50% basal and 50% prandial insulin using a basal-bolus regimen with rapid-acting insulin analogs at meals and long-acting basal insulin once or twice daily.

Initial Dosing Strategy

The starting total daily insulin dose for metabolically stable adults with type 1 diabetes ranges from 0.4 to 1.0 units/kg, with 0.5 units/kg being the typical starting point 1, 2. For your 70-kg patient, this translates to approximately 35 units per day.

Basal-Bolus Distribution

Split the total daily dose as follows:

• Basal insulin: ~17-18 units (approximately 50% of total daily dose)
• Prandial insulin: ~17-18 units divided across three meals

Most patients with type 1 diabetes should be treated with multiple daily injections (MDI) of both prandial and basal insulin or continuous subcutaneous insulin infusion (CSII) 1.

Specific Insulin Regimen

Basal Insulin Component

• Use a long-acting basal analog (glargine or detemir) rather than NPH
• Start with 17-18 units once daily (can be given at dinner or bedtime)
• Long-acting analogs provide more steady plasma insulin concentrations and reduce hypoglycemia risk compared to NPH 3

Prandial Insulin Component

• Use rapid-acting insulin analogs (lispro, aspart, or glulisine) to reduce hypoglycemia risk 1
• Start with 4-6 units before each meal (total ~17-18 units/day)
• Dose should be matched to carbohydrate intake, premeal glucose levels, and anticipated physical activity 1

Titration Algorithm

For Basal Insulin:

• Set fasting plasma glucose goal (typically 80-130 mg/dL)
• Increase by 2 units every 3 days until fasting glucose reaches target without hypoglycemia 4
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% 4

For Prandial Insulin:

• Increase by 1-2 units or 10-15% if postprandial glucose remains elevated 4
• Adjust each meal dose independently based on 2-hour postprandial glucose readings
• Target postprandial glucose: 80-180 mg/dL

Carbohydrate Counting Formula:

Once stabilized, calculate carbohydrate factor (CarbF) using:

• CarbF = (2.6 × Weight in pounds) / Total Daily Dose
• For 70 kg (154 lbs): CarbF = (2.6 × 154) / 35 = approximately 11 grams of carbohydrate per unit of insulin 5

Correction Factor:

• Correction Factor = 1960 / Total Daily Dose
• For 35 units TDD: 1960/35 = approximately 56 mg/dL drop per unit of insulin 5

Important Clinical Considerations

Insulin Analog Selection

Rapid-acting analogs are strongly preferred over regular human insulin because they:

• Reduce hypoglycemia risk significantly 1
• Provide better postprandial glucose control 6
• Allow more flexible meal timing

Common Pitfalls to Avoid

1. Underinsulinization: The evidence shows poor glucose control is often related to being relatively underinsulinized, not overinsulinized 5

2. Overbasalization: Watch for signs including:

   • Elevated bedtime-to-morning glucose differential
   • High postprandial-to-preprandial differential
   • Frequent hypoglycemia
   • High glucose variability 4

3. Fixed dosing without adjustment: Insulin requirements change with puberty (higher doses needed), physical activity, illness, and other factors 1

Dose Adjustments for Special Circumstances

• Newly diagnosed patients: May require lower initial doses (as low as 0.4 units/kg) due to residual endogenous insulin production 1, 2
• Diabetic ketoacidosis presentation: Higher weight-based starting doses needed 1
• Puberty: Significantly higher insulin doses often required 1

Expected Bolus-to-Basal Ratio Evolution

As therapy is optimized, expect the bolus-to-basal ratio to shift toward 60-70% bolus and 30-40% basal 7. This is normal and reflects adequate prandial coverage without overbasalization.

Monitoring and Follow-up

Assess adequacy of insulin dose at every visit 4. The landmark DCCT trial demonstrated that intensive therapy with MDI improved glucose control and resulted in:

• 57% reduction in cardiovascular events
• Decreased microvascular complications
• Modest reduction in all-cause mortality 1

However, these benefits require meticulous dose adjustment and patient education on carbohydrate counting, with the understanding that hypoglycemia risk increases with intensive management.